Target intelligence / Profile preview

Chromodomain Y-linked protein 2A (CDY2A)

Target
CDY2A
Molecular classification
Chromodomain protein, Histone acetyltransferase, Transcriptional corepressor
01

Overview

Chromodomain Y-linked protein 2A (CDY2A) is a Y-chromosome–encoded, intronless protein characterized by an N-terminal chromodomain and a C-terminal histone acetyltransferase domain. CDY2A is mainly expressed in testis, localized to the nucleus of late spermatids, and is implicated in facilitating histone hyperacetylation. This epigenetic modification is crucial for replacing histones with protamines—an essential step for sperm DNA compaction and maturation. Chromodomain proteins, including CDY2A, are components of heterochromatin-like complexes and can act as gene repressors. Mutations or deletions in CDY2A are implicated in certain types of spermatogenic failure (a cause of male infertility). There are no drugs known to interact with this molecule, and it does not serve as a current therapeutic target in clinical applications. There are paralogs such as CDY2B, and the chromodomain Y family is generally involved in chromatin regulation, but CDY2A itself has a highly specialized, testis-specific function.

Other names
Testis-specific chromodomain protein Y 2CDY2ACDY2Y chromosome chromodomain protein 2AChromodomain protein, Y-linked, 2AChromodomain protein, Y chromosome, 2
02

Mechanism of action

No drugs target CDY2A directly; known mechanisms are epigenetic/chromatin regulation by the endogenous protein

03

Biological functions

Epigenetic regulation of chromatin structure via chromodomain bindingHistone acetyltransferase activity (may acetylate histones)Transcriptional repression in heterochromatin-like complexesIn spermatids, participates in the histone-to-protamine transition needed for sperm chromatin packaging
04

Disease associations

Spermatogenic failure (male infertility)Possibly linked to cancer (breast cancer cell proliferation via CDYL2a, based on functional homology and recent CDYL2 data)Possible association with other diseases, but direct links to therapeutic intervention are limited
05

Safety considerations

None reported; CDY2A is not a therapeutic target
06

Interacting drugs

None reported in literature or clinical databases to date
07

Biomarkers

No established clinical biomarkers for patient selection or efficacy monitoring

Beyond the preview

Go deeper on Chromodomain Y-linked protein 2A (CDY2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromodomain Y-linked protein 2A (CDY2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call